|
CNOT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.34089999957044E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62173999999071E-05 |
| Normal-vs-Stage2 |
1.814480E-04 |
| Normal-vs-Stage3 |
2.15999999997329E-07 |
| Normal-vs-Stage4 |
1.73129999225807E-09 |
| Stage1-vs-Stage2 |
5.843200E-01 |
| Stage1-vs-Stage3 |
1.192210E-01 |
| Stage1-vs-Stage4 |
3.564800E-03 |
| Stage2-vs-Stage3 |
6.128800E-01 |
| Stage2-vs-Stage4 |
1.523580E-01 |
| Stage3-vs-Stage4 |
2.083400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.90739999994527E-06 |
| Normal-vs-AfricanAmerican |
2.782000E-02 |
| Normal-vs-Asian |
2.661900E-03 |
| Caucasian-vs-AfricanAmerican |
2.725600E-01 |
| Caucasian-vs-Asian |
2.757000E-01 |
| AfricanAmerican-vs-Asian |
7.794200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.46979999960229E-07 |
| Normal-vs-Female |
3.86550000008867E-07 |
| Male-vs-Female |
7.309200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.8393399999983E-05 |
| Normal-vs-Age(41-60Yrs) |
3.44139999997051E-06 |
| Normal-vs-Age(61-80Yrs) |
3.57570000275587E-08 |
| Normal-vs-Age(81-100Yrs) |
2.296500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.222800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.034500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.447400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.609570E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.062000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.941600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.610500E-02 |
| Classical-VS-Follicular |
2.138600E-01 |
| Classical-VS-Other |
5.353400E-01 |
| Classical-VS-Normal |
1.68641999999108E-05 |
| Tall-VS-Follicular |
4.021400E-01 |
| Tall-VS-Other |
5.869200E-01 |
| Tall-VS-Normal |
2.95119999993432E-07 |
| Follicular-VS-Other |
9.987400E-01 |
| Follicular-VS-Normal |
1.185560E-04 |
| Other-VS-Normal |
3.242000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.84259999988801E-07 |
| Normal-vs-N1 |
9.74420000021681E-07 |
| N0-vs-N1 |
7.156400E-01 |
|
|
